Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives

Simple item page
dc.contributor.authorShapiro S.
dc.contributor.authorRosenberg L.
dc.contributor.authorHoffman M.
dc.contributor.authorTruter H.
dc.contributor.authorCooper D.
dc.contributor.authorRao S.
dc.contributor.authorDent D.
dc.contributor.authorGudgeon A.
dc.contributor.authorVan Zyl J.
dc.contributor.authorKatzenellenbogen J.
dc.contributor.authorBailie R.
dc.date.accessioned2011-05-15T16:15:20Z
dc.date.available2011-05-15T16:15:20Z
dc.date.issued2000
dc.description.abstractRecent studies have suggested that progestogen-only contraceptives and combined estrogen/progestogen oral contraceptives (COCs) may increase the risk of breast cancer among women less than 35 years of age or among recent users. The authors conducted a case-control study, in which cases of breast cancer (n = 419) and controls (n = 1,625) hospitalized for conditions unrelated to contraceptive use were interviewed from 1994 to 1997 in hospitals in greater Cape Town, South Africa. The women were aged 20-54 years, resided in a defined area around Cape Town, and were Black or of mixed racial descent. The relative risk for exposure to injectable progestogen contraceptives (IPCs), mostly depot medroxyprogesterone acetate, was 0.9 (95% confidence interval (CI) 0.7, 1.2). There were no consistent associations within categories of age or recency or duration of use. For exposure to COCs, the overall relative risk was 1.2 (95% CI 1.0, 1.5). Among women below age 35 years, the relative risk was 1.7 (95% CI 1.0, 3.0), and it was unrelated to the duration or recency of use. The findings suggest that IPCs do not increase the risk of breast cancer, and that COCs may increase the risk among women below age 35 years, although bias cannot be excluded.
dc.description.versionArticle
dc.identifier.citationAmerican Journal of Epidemiology
dc.identifier.citation151
dc.identifier.citation4
dc.identifier.issn00029262
dc.identifier.urihttp://hdl.handle.net/10019.1/13290
dc.subjectestrogen
dc.subjectmedroxyprogesterone acetate
dc.subjectprogesterone
dc.subjectadult
dc.subjectage
dc.subjectarticle
dc.subjectbreast cancer
dc.subjectcancer incidence
dc.subjectcancer risk
dc.subjectcontraception
dc.subjectcontrolled study
dc.subjectfemale
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectpopulation exposure
dc.subjectSouth Africa
dc.subjectAdult
dc.subjectAfrican Americans
dc.subjectAfrican Continental Ancestry Group
dc.subjectBreast Neoplasms
dc.subjectCase-Control Studies
dc.subjectContraceptives, Oral, Combined
dc.subjectFemale
dc.subjectHumans
dc.subjectInjections, Intramuscular
dc.subjectMedroxyprogesterone 17-Acetate
dc.subjectMiddle Aged
dc.subjectProgesterone Congeners
dc.subjectRisk Factors
dc.subjectSouth Africa
dc.titleRisk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Tygerberg Hospital Publications